Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

Real-time Quote. Real-time Tradegate - 07/27 10:03:38 pm
98.165 EUR   +0.15%
07/26 MERCK KGAA : Biopharma Innovation Cup Honors Young Scientists
07/25 MERCK : Ethiopia Receives 14 Million Praziquantel Tablets
07/18 MERCK KGAA : Darmstadt, Germany Receives European Medicines Agency A..
News SummaryMost relevantAll newsSector news 

Merck KGaA : Merck Strengthens its Presence in China with New Pharmaceutical Manufacturing Facility

share with twitter share with LinkedIn share with facebook
share via e-mail
11/15/2013 | 08:24am CEST

Darmstadt / Germany, Nantong / China, November 15, 2013 - Merck announced today a € 80 million investment in a new pharmaceutical manufacturing facility, to be located in the Nantong Economical Technological Development Area (NETDA), in the Greater Shanghai region (Yangtze River Delta area).

"This further investment in China reflects Merck's long-term commitment to the country where our group has been present for 80 years," said Belén Garijo, President and Chief Executive Officer of Merck Serono, the biopharmaceutical division of Merck. "We are proud to be one of the first multinational companies investing in a local site focused on the manufacturing of medicines referenced in China's essential drug list, and serve the country's expanding healthcare needs in the areas of diabetes, cardiovascular diseases and thyroid disorders, by bringing high-quality medicines made in China to a broader population, in full alignment with the Chinese government's goal to increase access to quality products."
The new facility will focus on the bulk production and packaging of Glucophage®, Concor® and Euthyrox®, Merck's leading brands for the treatment of diabetes, cardiovascular diseases and thyroid disorders respectively. Located in NETDA's BioSpark, a high-tech industrial park designed to accommodate all aspects of the life science industry, the new facility will cover an area of 40,000 square meters, with a possible 20,000 square meters extension. The construction of the site is scheduled to start in 2014 and to be completed in 2016, and start commercial production in 2017. The site will be designed to comply with the highest international quality standards. The preservation of the environment will also be a critical consideration in the facility's construction, with a maximization of resource efficiency and minimized waste generation during the manufacturing process.

"This new facility will become Merck Serono's second largest pharmaceutical manufacturing site in the world and will help ensure that our medicines will always be available to patients who rely on them, which is a key priority for Merck Serono," added Allan Gabor, General Manager and Managing Director of Merck Serono in China. "With our research center, our development capabilities, our commercial presence and this new manufacturing facility, we are building for the future in China by investing across our value chain."

As part of its 80-year history in China, Merck has made significant investments in the country. Over the past five years only, investments for the Merck Serono division included:
- A research center in Beijing, focused on biomarker research, including pharmacogenomics and bioanalytics, which is part of Merck Serono's stratified medicine approach;
- Enhanced clinical development capabilities, covering over 400 key clinical study sites and having recruited over 10,000 patients accumulatively across China;
- Increased commercial presence to better serve patients and healthcare providers;
- An extensive network of collaborations with leading academic and medical institutions, as well as local companies; Merck Serono's latest collaboration agreement with a Chinese company, announced on November 13, 2013, is a second co-development and commercialization agreement with BeiGene, which will further strengthen the two companies existing collaboration in oncology.
Recent investments for other divisions of the Merck group include the Merck Millipore Biopharmaceutical Technical and Training Centre and a soon to be opened Liquid Crystals manufacturing facility, both located in Shanghai.

About Merck Serono China
Headquartered in Beijing, Merck Serono China currently employs 1,250 people in the country. Merck Serono China offers a portfolio of medicines addressing some of the key rising healthcare needs of the Chinese population, including the division's leading brands serving patients with cancer (Erbitux®), infertility (Gonal-f®), as well as cardiometabolic diseases (Glucophage®, Concor®, Euthyrox®).

About Merck Serono
Merck Serono is the biopharmaceutical division of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.
Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology.
For more information, please visit www.merckserono.com.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK KGAA
07/26 MERCK KGAA : Biopharma Innovation Cup Honors Young Scientists
07/25 MERCK : Ethiopia Receives 14 Million Praziquantel Tablets
07/25 MERCK : Ethiopia Receives 14 Million Praziquantel Tablets Around 23% of Ethiopia..
07/18 MERCK KGAA : Darmstadt, Germany Receives European Medicines Agency Acceptance fo..
07/14 MERCK KGAA : EMD Serono Commits EUR1.5 million to the Grant for Fertility Innova..
07/14 MERCK KGAA : Recent Findings from Merck KGaA Provides New Insights into Fenofibr..
07/13 MERCK KGAA : Advances Water Purification Systems with New High-Throughput Line
07/12 MERCK KGAA : Expands Excipients Portfolio, Adding Polymers for Sustained Release..
07/11 MERCK : and University of Nairobi to Start Medical Oncology Fellowship Program
07/10 MERCK : and University of Nairobi to Start Medical Oncology Fellowship Program M..
More news
Sector news : Specialty & Advanced Pharmaceuticals
11:00pDJALERE : Faces Criminal Probe Over Medicare, Medicaid Billing -- Update
10:56pDJAmgen Profit Rises 13%, 2016 Outlook Raised
10:56pDJALERE : Faces Criminal Probe Over Medicare, Medicaid Billing
10:36pDJFacebook Posts Strong Profit and Revenue Growth
09:45p Teva purchase of Allergan generics business gets OK with conditions
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
07/18 Merck's marketing application for Cladribine tablets accepted for review in E..
07/06 Late-stage study commences assessing Merck KGaA and Pfizer's avelumab + chemo..
07/05 OneCrinone reproductive treatment approved in Japan
06/24 Sector Licks Its Brexit Wounds
06/24 Eylea Combinations And Array's Play For Melanoma
Financials (€)
Sales 2016 15 078 M
EBIT 2016 3 252 M
Net income 2016 1 663 M
Debt 2016 10 869 M
Yield 2016 1,24%
P/E ratio 2016 24,74
P/E ratio 2017 23,06
EV / Sales 2016 1,56x
EV / Sales 2017 1,40x
Capitalization 12 668 M
More Financials
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 99,0 €
Spread / Average Target 1,00%
Consensus details
EPS Revisions
More Estimates Revisions
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Laszlo Radvanyi Senior Vice President & Head-Research
Crocifissa Attardo Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA9.43%13 929
ABBVIE INC8.79%104 239
BIOGEN INC-6.30%62 896
KYOWA HAKKO KIRIN CO L..-0.89%10 467
More Results